442 related articles for article (PubMed ID: 26132314)
1. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
[TBL] [Abstract][Full Text] [Related]
2. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde S; Kristoffersen EK; Sapkota D; Risa K; Dahl O; Bruland O; Mella O; Fluge Ø
PLoS One; 2016; 11(8):e0161226. PubMed ID: 27536947
[TBL] [Abstract][Full Text] [Related]
3. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Fluge Ø; Rekeland IG; Lien K; Thürmer H; Borchgrevink PC; Schäfer C; Sørland K; Aßmus J; Ktoridou-Valen I; Herder I; Gotaas ME; Kvammen Ø; Baranowska KA; Bohnen LMLJ; Martinsen SS; Lonar AE; Solvang AH; Gya AES; Bruland O; Risa K; Alme K; Dahl O; Mella O
Ann Intern Med; 2019 May; 170(9):585-593. PubMed ID: 30934066
[TBL] [Abstract][Full Text] [Related]
4. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.
Fluge Ø; Bruland O; Risa K; Storstein A; Kristoffersen EK; Sapkota D; Næss H; Dahl O; Nyland H; Mella O
PLoS One; 2011; 6(10):e26358. PubMed ID: 22039471
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Rekeland IG; Fluge Ø; Alme K; Risa K; Sørland K; Mella O; de Vries A; Schjøtt J
Clin Ther; 2019 May; 41(5):806-814. PubMed ID: 30502905
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.
Fluge Ø; Mella O
BMC Neurol; 2009 Jul; 9():28. PubMed ID: 19566965
[TBL] [Abstract][Full Text] [Related]
7. Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.
Mensah F; Bansal A; Berkovitz S; Sharma A; Reddy V; Leandro MJ; Cambridge G
Clin Exp Immunol; 2016 May; 184(2):237-47. PubMed ID: 26646713
[TBL] [Abstract][Full Text] [Related]
8. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
[TBL] [Abstract][Full Text] [Related]
9. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.
Rekeland IG; Fosså A; Lande A; Ktoridou-Valen I; Sørland K; Holsen M; Tronstad KJ; Risa K; Alme K; Viken MK; Lie BA; Dahl O; Mella O; Fluge Ø
Front Med (Lausanne); 2020; 7():162. PubMed ID: 32411717
[No Abstract] [Full Text] [Related]
10. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease.
Sotzny F; Blanco J; Capelli E; Castro-Marrero J; Steiner S; Murovska M; Scheibenbogen C;
Autoimmun Rev; 2018 Jun; 17(6):601-609. PubMed ID: 29635081
[TBL] [Abstract][Full Text] [Related]
11. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Sato M; Kamei K; Ogura M; Ishikura K; Ito S
Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
[TBL] [Abstract][Full Text] [Related]
12. Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.
Cash A; Kaufman DL
J Transl Med; 2022 Jun; 20(1):295. PubMed ID: 35764955
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
15. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.
Memon AB; Javed A; Caon C; Srivastawa S; Bao F; Bernitsas E; Chorostecki J; Tselis A; Seraji-Bozorgzad N; Khan O
PLoS One; 2018; 13(1):e0190425. PubMed ID: 29309416
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.
Morris MC; Cooney KE; Sedghamiz H; Abreu M; Collado F; Balbin EG; Craddock TJA; Klimas NG; Broderick G; Fletcher MA
Clin Ther; 2019 Apr; 41(4):656-674.e4. PubMed ID: 30929860
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
19. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
20. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
